Blood test guided treatment after stomach cancer surgery
Part of Cancer, Digestive system clinical trials.
This study looks at using a blood test that finds tiny bits of cancer DNA to decide if you need extra chemotherapy after surgery. It aims to make treatment more personalized and reduce side effects for people with locally advanced stomach cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have stomach cancer or cancer at the gastroesophageal junction, at a stage that has not spread far (stage II to IVA), and it should be possible to remove the tumor with surgery.
- You should be in generally good health (ECOG performance status 0 to 2) and fit for surgery.
- You must provide a tissue sample from your tumor (taken during an endoscopy) for genetic testing.
- You must have adequate blood and organ function, which will be checked by blood tests.
- You cannot have had any previous treatment for this cancer before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether using a blood test to find tiny amounts of cancer DNA after initial treatment can guide decisions about further therapy for people with stomach cancer. The goal is to personalize follow-up treatment to reduce the chance of cancer returning.
This study uses special blood tests to detect cancer DNA and help doctors decide the best treatment plan for gastric cancer. The goal is to improve outcomes by personalizing therapy based on how your cancer responds.
This study tracks a simple blood test to look for tiny traces of cancer DNA after stomach cancer surgery. It aims to see if this test can catch any cancer coming back early, so you can get treatment sooner.
This study tests a new way to guide treatment after surgery for stomach cancer. It uses a blood test to look for tiny pieces of cancer DNA, and then gives extra treatment only to people who still have signs of cancer. The goal is to prevent the cancer from coming back.
This trial studies blood-based biomarkers to help doctors choose the best individualized surgical treatment for gastroesophageal junction adenocarcinoma. If you qualify, you’ll get standard care plus additional testing to see whether the blood results can guide surgery more precisely.
This trial checks whether a blood test after surgery (ctDNA) can help decide if you should receive additional “adjuvant” treatment for stomach, gastroesophageal junction, or lower esophagus cancer that has HER2-positive tumors. It may help reduce the chance of cancer coming back by tailoring therapy to your risk based on the ctDNA result.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.